acid, are far from satisfaction. 3 Lately, some pilot studies have addressed the efficacy of Q-switched Nd:YAG laser (QSNY) 4 or the combination therapy of QSNY with topical hydroquinone and oral tranexamic acid (TA). 5 However, since most of the recalcitrant Riehl's melanosis patients suffer from inflammation featured as erythema and itching, QSNY or intense pulsed light (IPL) treatment may pose a risk of developing post-inflammatory hyperpigmentation, especially in patients with darker Fitzpatrick skin types. 6, 7 Thus, in this study, we attempted to treat Riehl's melanosis with a much safer and mild combination therapy of oral TA and Glycyrrhizin compound.
| MATERIAL S AND ME THODS

| Patients
A total of 10 Chinese patients diagnosed with Riehl's melanosis on face or neck were enrolled. All of the 10 patients were aged be- 
| Study design
A prospective pilot study was performed for 6 months to evaluate the efficacy of a combination therapy of oral administration of TA and Glycyrrhizin compound for Riehl's melanosis. After checking patients' medical history and eliminating contraindications such as using combination hormonal contraceptives, having active thromboembolic disease, history or intrinsic risk of thrombosis or thromboembolism for TA and hyperaldosteronism, myopathy, hypokalemia, and end-stage liver cirrhosis for Glycyrrhizin compound, we treated all enrolled patients with 250 mg TA twice a day and 50 mg
Glycyrrhizin compound three times a day orally for 3 months. In order to minimize Glycyrrhizin-related adverse reactions, such as reduction of blood potassium levels and increase of blood pressure, oral Glycyrrhizin compound was withdrawn at 3-month follow-up when skin inflammation was almost resolved as all of the 10 patients described disappearance of erythema and pruritus. Afterward, 250 mg TA was given twice a day orally alone for another 3 months to further reduce pigmentation.
| Clinical assessment
Riehl's melanosis lesions were imaged by reflectance confocal mi- improvement), "marked improvement" (51%-75% improvement), "moderate improvement" (25%-50% improvement), "minimal improvement" (0%-25% improvement), and "stable or worsening" (no improvement or aggravation).
| Statistical analysis
Mean values of MI and EI from baseline to final visit were evaluated using Student's t-test. Difference was considered statistically significant when P < 0.05. All statistical analyses were performed by SPSS 21.0 ( SPSS Inc., Chicago, IL, USA).
| RE SULTS
| Clinical assessment
Among 10 patients, seven people (70%) received "marked improvement," 2 (20%) received "moderate improvement," while 1 (10%)
received "minimal improvement." None of the patients were scored
as "almost clear" or "stable or worsening" (Figure 1 ). The scale was graded by both physicians and patients themselves at final visit, and all patients' subjective grades were consistent with physicians' assessments (0/10: "almost clear," 7/10: "marked improvement," 2/10:
"moderate improvement," 1/10: "minimal improvement," and 0/10: More interestingly, when comparing the mean MI and EI at 3-month and 6-month visit, we found mean MI and EI of 10 Riehl's melanosis patients were also significantly decreased (P < 0.05 compared with 3-month visit), which indicated that oral administration of TA therapy alone could alleviate pigment and erythema in Riehl's melanosis patients to some extent, even after the first 3-month treatment.
| Reflectance confocal microscopy and dermatoscopy analyses
Before treatment, dermoscopy revealed slight scales, follicular plugs within the hair follicles, pseudonetwork-like dark brown dots or granules, and telangiectatic vessels ( Figure 6 , column 1).
Meanwhile, RCM showed dilated vessels and infundibulum infil- 
| D ISCUSS I ON
TA, a plasmin inhibitor, is now widely used (off-label) in several pigmented diseases, especially melasma. 8 Generally, it was reported that TA could inhibit melanin synthesis in melanocytes by interfering with the melanocyte-keratinocyte interaction through the plasminogen/plasmin system. 9 TA also downregulates the activity of mast cells, which plays a crucial role in the process of pigmentation. 10 Recently, some studies have proved that TA could directly inhibit melanogenesis through suppressing the expression of prohormone convertase (PC2) and α-melanocyte-stimulating hormone (α-MSH) 11 and activating the ERK signaling pathway and the autophagy system in cultured melanoma B16-F1 cells. 12 In our study, the decrease of mean MI and the pigment granules support the potential value of oral intake of TA in the improvement of hyperpigmentation in Riehl's melanosis.
Meanwhile, some previous studies suggested that TA also had anti-angiogenic and anti-inflammatory functions. 10 It was
reported that TA could reduce the number of blood vessels in dermis, and inhibit neovascularization induced by basic fibroblast growth factor. 13 Since we have observed the decrease of mean EI even after the withdrawal of Glycyrrhizin compound ( Figure 5 ), it is likely that TA alone may also have potential values in the improvement of facial erythema apart from Glycyrrhizin compound.
What is more, it has been confirmed that vascularization itself also influences skin pigmentation in vivo, and dermal microvascular endothelial cells (HMVEC) could induce melanogenesis via the secretion of melanogenic cytokines like endothelin-1(ET-1).
14 Thus, we suppose that TA not only inhibits melanin synthesis via the direct effects on melanocytes, but also suppresses neovascularization, which indirectly promotes depigmentation.
In the present study, we treated the patients with TA in combination with Glycyrrhizin compound, pursuing for better depigmenting results. It was reported that Glycyrrhizin, a triterpene glycoside isolated from licorice root, has a wide range of pharmacological actions including anti-inflammation, anti-allergy, 15 anti-viral infection, 16 anti-carcinogenesis, 17 and anti-thrombin. 18 Glycyrrhizin could suppress systemic inflammation by inhibiting the migration and inducing apoptosis of monocytes through high mobility group box-1 protein (HMGB1) signaling pathway.
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Notably, HMGB1 has been well recognized as an important signaling molecule involved in both acute and chronic inflammation process. 20 Its expression was significantly increased in a variety of skin diseases, such as psoriasis, alopecia areata, vitiligo, atopic dermatitis, Henoch-Schönlein purpura (HSP), pemphigus, and drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DRESS). [21] [22] [23] [24] [25] Due to the similar pharmacological efficacy to corticosteroids but with milder side effects, Glycyrrhizin has been widely utilized in several dermatologic disorders for many years, such as active-stage generalized vitiligo, 26 psoriasis, 27 alopecia areata, 28 and is also reported to be effective in alleviating the symptoms of atopic dermatitis and systemic sclerosis in animal model. 29, 30 Based on the clinical F I G U R E 4 Mean Melanin Index of Riehl's melanosis patients.
At each visit, Melanin Index was examined on the same location of the same patient for three times. Mean Melanin Index of 10 Riehl's melanosis patients at every visit was shown. The data represented the mean ± SD *P < 0.05. **P < 0.01 observation that patients with recalcitrant Riehl's melanosis may present with facial erythema and itching, which are signs of local inflammation, we applied Glycyrrhizin compound 75 mg orally three times a day for all enrolled patients, aiming to alleviate the inflammatory reaction. Surprisingly, the obvious reduction of facial erythema and itchiness were observed in all Riehl's melanosis patients. However, the effects of Glycyrrhizin on pigmentation are still controversial. Some studies reported that Glycyrrhizin could protect human melanoma cells from UVB irradiation, 31 while others discovered that Glycyrrhizin could induce melanogenesis through cAMP signaling in B16 melanoma cells.
32
To our knowledge, this is the first report of the application of the combination therapy of oral TA and Glycyrrhizin compound in the treatment of refractory Riehl's melanosis. Due to the fact that the prevalence of Riehl's melanosis is not so common as melasma, and the prospective controlled study is extremely difficult to perform, this pilot study is of significance in guiding clinical practice and provides a new combination therapy that may be safe and effective in treating Riehl's melanosis.
F I G U R E 5
Mean Erythema Index of Riehl's melanosis patients. At each visit, Erythema Index was examined on the same location of the same patient for three times. Mean Erythema Index of 10 Riehl's melanosis patients at every visit was shown. The data represented the mean ± SD *P < 0.05. **P < 0.01
| Limitations
For a more convincing clinical study, the adoption of a control group is needed. Further studies with a larger study cohort with diverse ethnic backgrounds may be required for more detailed research.
| CON CLUS IONS
In conclusion, combined oral administration of TA and Glycyrrhizin compound may be an effective and safe therapy for patients with recalcitrant Riehl's melanosis.
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Chengfeng Zhang http://orcid.org/0000-0002-1302-5667 F I G U R E 6 Dermatoscopy and reflectance confocal microscopy of five Riehl's melanosis lesions. Dermatoscopy images were shown in the first and second column, and reflectance confocal microscopy images were shown in the third and fourth column. Typical microscopic features were labeled in the images (asterisk: telangiectatic vessels; arrow: pigment dots or granules; triangle: follicular plugs within the hair follicles; diamond: scales). Dermatoscopy: original magnification ×20. Reflectance confocal microscopy: original magnification ×30
